Cabergoline

Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It is taken by mouth.

Cabergoline is an ergot derivative and a potent dopamine D₂ receptor agonist.<ref>Template:Cite book</ref>

Cabergoline was patented in 1980 and approved for medical use in 1993.<ref name=Fis2006>Template:Cite book</ref> It is on the World Health Organization's List of Essential Medicines.<ref name="WHO23rd">Template:Cite book</ref>

Medical uses

• Lactation suppression
• Hyperprolactinemia<ref name=UKlabel>UK electronic Medicines Compendium Dostinex Tablets Last Updated on eMC Dec 23, 2013</ref>
• Adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas);
• Monotherapy of Parkinson's disease in the early phase;
• Combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson's disease;
• In some countries also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis and galactorrhea);
• Treatment of uterine fibroids.<ref>Template:Cite journal</ref><ref>Template:Cite journal </ref>
• Adjunctive therapy of acromegaly, cabergoline has low efficacy in suppressing growth hormone levels and is highly efficient in suppressing hyperprolactinemia that is present in 20-30% of acromegaly cases; growth hormone and prolactin are similar structurally and have similar effects in many target tissues, therefore targeting prolactin may help symptoms when growth hormone secretion cannot be sufficiently controlled by other methods;

Cabergoline is frequently used as a first-line agent in the management of prolactinomas due to its higher affinity for D₂ receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine, though in pregnancy bromocriptine is often still chosen since there is less data on safety in pregnancy for cabergoline.

Off-label

Cabergoline has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs, such as reduced libido and anorgasmia. It also has been suggested that it has a possible recreational use in reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession, and at least two scientific studies support those speculations.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>Template:Rp Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF).<ref>Template:Cite journal</ref> Also, a study on rats found that cabergoline reduces voluntary alcohol consumption, possibly by increasing GDNF expression in the ventral tegmental area.<ref>Template:Cite journal</ref> It may be used in the treatment of restless legs syndrome.Template:Citation needed. Oral administration of cabergoline was faced with gastrointestinal problems which cause poor compliance in patients. One of the preferred solutions is to use non-oral dosage forms like suppositories. Vaginal suppositories have ease of use and could hinder gastrointestinal effects of cabergoline.<ref>Template:Cite journal</ref>

Pregnancy and lactation

Relatively little is known about the effects of this medication during pregnancy and lactation. In some cases the related bromocriptine may be an alternative when pregnancy is expected.Template:Citation needed

• Pregnancy: available preliminary data indicates a somewhat increased rate of congenital abnormalities in patients who became pregnant while treated with cabergoline.Template:Citation needed. However, one study concluded that "foetal exposure to cabergoline through early pregnancy does not induce any increase in the risk of miscarriage or foetal malformation."<ref>Template:Cite journal</ref>
• Lactation: In rats cabergoline was found in the maternal milk. Since it is not known if this effect also occurs in humans, breastfeeding is usually not recommended if/when treatment with cabergoline is necessary.
• Lactation suppression: In some countries cabergoline (Dostinex) is sometimes used as a lactation suppressant. It is also used in veterinary medicine to treat false pregnancy in dogs.

Contraindications

• Hypersensitivity to ergot derivatives
• Pediatric patients (no clinical experience)
• Severely impaired liver function or cholestasis
• Concomitant use with drugs metabolized mainly by CYP450 enzymes such as erythromycin and ketoconazole, because increased plasma levels of cabergoline may result (although cabergoline undergoes minimal CYP450 metabolism).
• Cautions: severe cardiovascular disease, Raynaud's disease, gastroduodenal ulcers, active gastrointestinal bleeding, hypotension.

Side effects

Side effects are mostly dose dependent. Much more severe side effects are reported for treatment of Parkinson's disease and (off-label treatment) for restless leg syndrome which both typically require very high doses. The side effects are considered mild when used for treatment of hyperprolactinemia and other endocrine disorders or gynecologic indications where the typical dose is one hundredth to one tenth that for Parkinson's disease.Template:Citation needed

Cabergoline requires slow dose titration (2–4 weeks for hyperprolactinemia, often much longer for other conditions) to minimize side effects. The extremely long bioavailability of the medication may complicate dosing regimens during titration and require particular precautions.

Cabergoline is considered the best tolerable option for hyperprolactinemia treatment although the newer and less tested quinagolide may offer similarly favourable side effect profile with quicker titration times.

Approximately 200 patients with newly diagnosed Parkinson's disease participated in a clinical study of cabergoline monotherapy.<ref>Template:Cite journal</ref> Seventy-six (76) percent reported at least one side effect. These side effects were chiefly mild or moderate:

• GI tract: Side effects were extremely frequent. Fifty-three percent of patients reported side effects. Very frequent: Nausea (30%), constipation (22%), and dry mouth (10%). Frequent: Gastric irritation (7%), vomiting (5%), and dyspepsia (2%).
• Psychiatric disturbances and central nervous system (CNS): Altogether 51 percent of patients were affected. Very frequent: Sleep disturbances (somnolence 18%, insomnia 11%), vertigo (27%), and depression (13%). Frequent: dyskinesia (4%) and hallucinations (4%).
• Cardiovascular: Approximately 30 percent of patients experienced side effects. Most frequent were hypotension (10%), peripheral edema (14%) and non-specific edema (2%). Arrhythmias were encountered in 4.8%, palpitations in 4.3%, and angina pectoris in 1.4%.

In a combination study with 2,000 patients also treated with levodopa, the incidence and severity of side effects was comparable to monotherapy. Encountered side effects required a termination of cabergoline treatment in 15% of patients. Additional side effects were infrequent cases of hematological side effects, and an occasional increase in liver enzymes or serum creatinine without signs or symptoms.

As with other ergot derivatives, pleuritis, exudative pleura disease, pleura fibrosis, lung fibrosis, and pericarditis are seen. These side effects are noted in less than 2% of patients. They require immediate termination of treatment. Clinical improvement and normalization of X-ray findings are normally seen soon after cabergoline withdrawal. It appears that the dose typically used for treatment of hyperprolactinemia is too low to cause this type of side effects.

Valvular heart disease

In two studies published in the New England Journal of Medicine on January 4, 2007, cabergoline was implicated along with pergolide in causing valvular heart disease.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref> As a result of this, the FDA removed pergolide from the U.S. market on March 29, 2007.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Since cabergoline is not approved in the U.S. for Parkinson's Disease, but for hyperprolactinemia, the drug remains on the market. The lower doses required for treatment of hyperprolactinemia have been found to be not associated with clinically significant valvular heart disease or cardiac valve regurgitation.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Interactions

{{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= {{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= Template:Ambox }} }} No interactions were noted with levodopa or selegiline. The drug should not be combined with other ergot derivatives. Dopamine antagonists such as antipsychotics and metoclopramide counteract some effects of cabergoline. The use of antihypertensive drugs should be intensively monitored because excessive hypotension may result from the combination.

Pharmacology

Pharmacodynamics

Template:Nowrap

Site	Affinity (Ki [nM])	Efficacy (Emax [%])	Action
D1	214–32,000	?	Agonist
D2S	0.5–0.62	102	Superagonist
D2L	0.95	75	Partial agonist
D3	0.80–1.0	86	Full agonist
D4	56	49	Partial agonist
D5	22	?	Agonist
5-HT1A	1.9–20	93	Full agonist
5-HT1B	479	102	Superagonist
5-HT1D	8.7	68	Partial agonist
5-HT2A	4.6–6.2	94	Full agonist
5-HT2B	1.2–9.4	98	Full agonist
5-HT2C	5.8–692	96	Full agonist
5-HT3	>10,000	–	–
5-HT4	3,000	?	?
5-HT6	1,300	?	?
5-HT7	2.5	?	Antagonist
α1A	288–>10,000	0	Binder
α1B	60–1,000	?	Binder
α1D	166	?	Binder
α2A	12–132	0	Antagonist
α2B	17–72	0	Antagonist
α2C	22–364	0	Antagonist
α2D	3.6	?	?
H1	1,380	?	?
M1	>10,000	–	–
SERT	>10,000	–	–
Notes: All sites are human except α2D-adrenergic, which is rat (no human counterpart).<ref name="pmid12388666" /> Negligible affinity (>10,000 nM) for various other receptors (β1- and β2-adrenergic, adenosine, GABA, glutamate, glycine, nicotinic acetylcholine, opioid, prostanoid).<ref name="pmid18992242" /> Sources: <ref name="pmid12388666">Template:Cite journal</ref><ref name="pmid12388667">Template:Cite journal</ref><ref name="pmid12388668">Template:Cite journal</ref><ref name="pmid18992242">Template:Cite journal</ref><ref name="PDSPKiDatabase">{{#invoke:citation/CS1|citation				CitationClass=web }}</ref>

Cabergoline is a long-acting dopamine D₂ receptor agonist. In-vitro rat studies show a direct inhibitory effect of cabergoline on the prolactin secretion in the lactotroph cells of the pituitary gland and cabergoline decreases serum prolactin levels in reserpinized rats.Template:Citation needed Although cabergoline is commonly described principally as a D₂ receptor agonist, it also possesses significant affinity for the dopamine D₃, and D₄, serotonin 5-HT_1A, 5-HT_2A, 5-HT_2B, and 5-HT_2C, and α₂-adrenergic receptors, as well as moderate/low affinity for the dopamine D₁, serotonin 5-HT₇, and α₁-adrenergic receptors.<ref name="pmid12388666" /><ref name="pmid18992242" /><ref name="PDSDKiDB">National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Jul 24]. ChapelHill (NC): University of North Carolina. 1998-2013. Available from: {{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Cabergoline functions as a partial or full agonist at all of these receptors except for the 5-HT₇, α₁-adrenergic, and α₂-adrenergic receptors, where it acts as an antagonist.<ref name="pmid12388667" /><ref name="pmid12388668" /><ref name="pmid18992242" /> Cabergoline has been associated with cardiac valvulopathy due to activation of 5-HT_2B receptors.<ref name="pmid24361689">Template:Cite journal</ref>

Ergot derivatives like cabergoline have been described as non-hallucinogenic in spite of acting as serotonin 5-HT_2A receptor agonists.<ref name="GumpperRoth2024">Template:Cite journal</ref>

Pharmacokinetics

{{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= {{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= Template:Ambox }} }}

Following a single oral dose, resorption of cabergoline from the gastrointestinal (GI) tract is highly variable, typically occurring within 0.5 to 4 hours. Ingestion with food does not alter its absorption rate. Human bioavailability has not been determined since the drug is intended for oral use only. In mice and rats the absolute bioavailability has been determined to be 30 and 63 percent, respectively. Cabergoline is rapidly and extensively metabolized in the liver and excreted in bile and to a lesser extent in urine. All metabolites are less active than the parental drug or inactive altogether. The human elimination half-life is estimated to be 63 to 68 hours in patients with Parkinson's disease and 79 to 115 hours in patients with pituitary tumors. Average elimination half-life is 80 hours. The metabolism of cabergoline is mediated by unidentified enzymes via a hepatic route and mainly consists of hydrolysis and oxidation by the alkylurea group and oxidation at the alkene.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref>

File:CabergolineMetabolism.png

History

Cabergoline was first synthesized by scientists working for the Italian drug company Farmitalia-Carlo Erba in Milan who were experimenting with semisynthetic derivatives of the ergot alkaloids, and a patent application was filed in 1980.<ref name=SuppProtec>Council regulation (EEC) no 1768/92 in the matter of Application No SPC/GB94/012 for a Supplementary Protection Certificate in the name of Farmitalia Carlo Erba S. r. l.</ref><ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>US Patent 4526892 - Dimethylaminoalkyl-3-(ergoline-8'.beta.carbonyl)-ureas</ref> The first publication was a scientific abstract at the Society for Neuroscience meeting in 1991.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Farmitalia-Carlo Erba was acquired by Pharmacia in 1993,<ref>Staff. News: Farmitalia bought by Kabi PharmaciaTemplate:Dead link. Ann Oncol (1993) 4 (5): 345.</ref> which in turn was acquired by Pfizer in 2003.<ref>Staff, CNN/Money. April 16, 2003 It's official: Pfizer buys Pharmacia </ref>

Cabergoline was first marketed in The Netherlands as Dostinex in 1992.<ref name=SuppProtec/> The drug was approved by the FDA on December 23, 1996.<ref>FDA approval historyTemplate:Dead linkTemplate:Cbignore</ref> It went generic in late 2005 following US patent expiration.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Society and culture

Brand names

Brand names of cabergoline include Cabaser, Dostinex, Galastop (veterinary), and Kelactin (veterinary), among others.<ref name="Drugs.com">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Research

Cabergoline was studied in one person with Cushing's disease, to lower adrenocorticotropic hormone (ACTH) levels and cause regression of ACTH-producing pituitary adenomas.<ref>Template:Cite journal</ref>